Adriano S Martins1, Michelle S Parvatiyar2, Han-Zhong Feng3, J Martijn Bos4, David Gonzalez-Martinez1, Milica Vukmirovic1, Rajdeep S Turna1, Marcos A Sanchez-Gonzalez1,5, Crystal-Dawn Badger1, Diego A R Zorio6, Rakesh K Singh7, Yingcai Wang2, J-P Jin3, Michael J Ackerman4,8,9, Jose R Pinto1. 1. Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee. 2. Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, Miami, FL. 3. Department of Physiology, Wayne State University School of Medicine, Detroit, MI. 4. Department of Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN. 5. Department of Biomedical Sciences, Larkin Health Sciences Institute, South Miami, FL. 6. Department of Chemistry & Biochemistry, College of Medicine, Florida State University, Tallahassee. 7. Translational Science Laboratory, College of Medicine, Florida State University, Tallahassee. 8. Department of Medicine/Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. 9. Department of Pediatrics/Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: Mutations in thin-filament proteins have been linked to hypertrophic cardiomyopathy, but it has never been demonstrated that variants identified in the TNNC1 (gene encoding troponin C) can evoke cardiac remodeling in vivo. The goal of this study was to determine whether TNNC1 can be categorized as an hypertrophic cardiomyopathy susceptibility gene, such that a mouse model can recapitulate the clinical presentation of the proband. METHODS AND RESULTS: The TNNC1-A8V proband diagnosed with severe obstructive hypertrophic cardiomyopathy at 34 years of age exhibited mild-to-moderate thickening in left and right ventricular walls, decreased left ventricular dimensions, left atrial enlargement, and hyperdynamic left ventricular systolic function. Genetically engineered knock-in (KI) mice containing the A8V mutation (heterozygote=KI-TnC-A8V(+/-); homozygote=KI-TnC-A8V(+/+)) were characterized by echocardiography and pressure-volume studies. Three-month-old KI-TnC-A8V(+/+) mice displayed decreased ventricular dimensions, mild diastolic dysfunction, and enhanced systolic function, whereas KI-TnC-A8V(+/-) mice displayed cardiac restriction at 14 months of age. KI hearts exhibited atrial enlargement, papillary muscle hypertrophy, and fibrosis. Liquid chromatography-mass spectroscopy was used to determine incorporation of mutant cardiac troponin C (≈ 21%) into the KI-TnC-A8V(+/-) cardiac myofilament. Reduced diastolic sarcomeric length, increased shortening, and prolonged Ca(2+) and contractile transients were recorded in intact KI-TnC-A8V(+/-) and KI-TnC-A8V(+/+) cardiomyocytes. Ca(2+) sensitivity of contraction in skinned fibers increased with mutant gene dose: KI-TnC-A8V(+/+)>KI-TnC-A8V(+/-)>wild-type, whereas KI-TnC-A8V(+/+) relaxed more slowly on flash photolysis of diazo-2. CONCLUSIONS: The TNNC1-A8V mutant increases the Ca(2+)-binding affinity of the thin filament and elicits changes in Ca(2+) homeostasis and cellular remodeling, which leads to diastolic dysfunction. These in vivo alterations further implicate the role of TNNC1 mutations in the development of cardiomyopathy.
BACKGROUND: Mutations in thin-filament proteins have been linked to hypertrophic cardiomyopathy, but it has never been demonstrated that variants identified in the TNNC1 (gene encoding troponin C) can evoke cardiac remodeling in vivo. The goal of this study was to determine whether TNNC1 can be categorized as an hypertrophic cardiomyopathy susceptibility gene, such that a mouse model can recapitulate the clinical presentation of the proband. METHODS AND RESULTS: The TNNC1-A8V proband diagnosed with severe obstructive hypertrophic cardiomyopathy at 34 years of age exhibited mild-to-moderate thickening in left and right ventricular walls, decreased left ventricular dimensions, left atrial enlargement, and hyperdynamic left ventricular systolic function. Genetically engineered knock-in (KI) mice containing the A8V mutation (heterozygote=KI-TnC-A8V(+/-); homozygote=KI-TnC-A8V(+/+)) were characterized by echocardiography and pressure-volume studies. Three-month-old KI-TnC-A8V(+/+) mice displayed decreased ventricular dimensions, mild diastolic dysfunction, and enhanced systolic function, whereas KI-TnC-A8V(+/-) mice displayed cardiac restriction at 14 months of age. KI hearts exhibited atrial enlargement, papillary muscle hypertrophy, and fibrosis. Liquid chromatography-mass spectroscopy was used to determine incorporation of mutant cardiac troponin C (≈ 21%) into the KI-TnC-A8V(+/-) cardiac myofilament. Reduced diastolic sarcomeric length, increased shortening, and prolonged Ca(2+) and contractile transients were recorded in intact KI-TnC-A8V(+/-) and KI-TnC-A8V(+/+) cardiomyocytes. Ca(2+) sensitivity of contraction in skinned fibers increased with mutant gene dose: KI-TnC-A8V(+/+)>KI-TnC-A8V(+/-)>wild-type, whereas KI-TnC-A8V(+/+) relaxed more slowly on flash photolysis of diazo-2. CONCLUSIONS: The TNNC1-A8V mutant increases the Ca(2+)-binding affinity of the thin filament and elicits changes in Ca(2+) homeostasis and cellular remodeling, which leads to diastolic dysfunction. These in vivo alterations further implicate the role of TNNC1 mutations in the development of cardiomyopathy.
Authors: Carolyn Y Ho; Begoña López; Otavio R Coelho-Filho; Neal K Lakdawala; Allison L Cirino; Petr Jarolim; Raymond Kwong; Arantxa González; Steven D Colan; J G Seidman; Javier Díez; Christine E Seidman Journal: N Engl J Med Date: 2010-08-05 Impact factor: 91.245
Authors: Robert D Gaffin; James R Peña; Marco S L Alves; Fernando A L Dias; Shamim A K Chowdhury; Lynley S Heinrich; Paul H Goldspink; Evangelia G Kranias; David F Wieczorek; Beata M Wolska Journal: J Mol Cell Cardiol Date: 2011-08-05 Impact factor: 5.000
Authors: Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann Journal: J Clin Invest Date: 2008-11-20 Impact factor: 14.808
Authors: Jose Renato Pinto; Michelle S Parvatiyar; Michelle A Jones; Jingsheng Liang; Michael J Ackerman; James D Potter Journal: J Biol Chem Date: 2009-05-12 Impact factor: 5.157
Authors: Ruth H Willott; Aldrin V Gomes; Audrey N Chang; Michelle S Parvatiyar; Jose Renato Pinto; James D Potter Journal: J Mol Cell Cardiol Date: 2009-11-12 Impact factor: 5.000
Authors: Jose Renato Pinto; Daniel P Reynaldo; Michelle S Parvatiyar; David Dweck; Jingsheng Liang; Michelle A Jones; Martha M Sorenson; James D Potter Journal: J Biol Chem Date: 2010-11-05 Impact factor: 5.157
Authors: Charles M Stevens; Kaveh Rayani; Gurpreet Singh; Bairam Lotfalisalmasi; D Peter Tieleman; Glen F Tibbits Journal: J Biol Chem Date: 2017-05-22 Impact factor: 5.157
Authors: Francisco J Alvarado; J Martijn Bos; Zhiguang Yuchi; Carmen R Valdivia; Jonathan J Hernández; Yan-Ting Zhao; Dawn S Henderlong; Yan Chen; Talia R Booher; Cherisse A Marcou; Filip Van Petegem; Michael J Ackerman; Héctor H Valdivia Journal: JCI Insight Date: 2019-03-05
Authors: Amanda M Dossat; Marcos A Sanchez-Gonzalez; Andrew P Koutnik; Stefano Leitner; Edda L Ruiz; Brittany Griffin; Jens T Rosenberg; Samuel C Grant; Francis D Fincham; Jose R Pinto; Mohamed Kabbaj Journal: FASEB J Date: 2017-02-24 Impact factor: 5.191
Authors: Henry G Zot; Javier E Hasbun; Clara A Michell; Maicon Landim-Vieira; Jose R Pinto Journal: Arch Biochem Biophys Date: 2016-03-11 Impact factor: 4.013
Authors: Srboljub M Mijailovich; Momcilo Prodanovic; Corrado Poggesi; Joseph D Powers; Jennifer Davis; Michael A Geeves; Michael Regnier Journal: J Mol Cell Cardiol Date: 2021-02-24 Impact factor: 5.000
Authors: Michelle S Parvatiyar; Alexandra J Brownstein; Rosemeire M Kanashiro-Takeuchi; Judd R Collado; Karissa M Dieseldorff Jones; Jay Gopal; Katherine G Hammond; Jamie L Marshall; Abel Ferrel; Aaron M Beedle; Jeffrey S Chamberlain; Jose Renato Pinto; Rachelle H Crosbie Journal: JCI Insight Date: 2019-04-30